TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11520478

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 9391998

Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day) plus calcium (500 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipriflavone (400 mg/day) plus conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 0
Study: 7961321

Group type: EXPERIMENTAL
Intervention: Methacholine inhalation challenge
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Yearly Dmin variation from age 13
Number of subjects: 350
Study: 3308571

Group type: EXPERIMENTAL
Intervention: One dose of cefoxitin (2 g)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Three doses of cefoxitin (2 g, 1 g, and 1 g)
Number of subjects: 138
Study: 28950380

Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Fibre-optic bronchoscopy
Number of subjects: 112
Study: 28437120

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 30
Study: 26427705

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg qid on day 0 and bid on days 1 to 7
Number of subjects: 5

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg bid for 7 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg qid for 7 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg bid in IMs
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg bid in PMs
Number of subjects: 5
Study: 24174910

Group type: EXPERIMENTAL
Intervention: Caudal block using 1 mL·kg(‐1) lidocaine (1%) after 2 mg·kg(‐1) ketamine IV
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2 mg·kg(‐1) ketamine IV only
Number of subjects: 40
Study: 21678045

Group type: EXPERIMENTAL
Intervention: Nonlower respiratory serious adverse events (NRSAEs) within 30 days post-exacerbation
Number of subjects: 3960

Group type: EXPERIMENTAL
Intervention: Nonlower respiratory serious adverse events (NRSAEs) within 180 days post-exacerbation
Number of subjects: 3960

Group type: EXPERIMENTAL
Intervention: Cardiac events as NRSAEs
Number of subjects: 3960
Study: 18344635

Group type: EXPERIMENTAL
Intervention: NPPV high-pressure group (n=16)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: NPPV low-pressure group (n=14)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 44
Study: 16555144

Group type: EXPERIMENTAL
Intervention: Family skills training
Number of subjects: 715

Group type: COMPARATOR
Intervention: Child skills training only
Number of subjects: 715

Group type: COMPARATOR
Intervention: Parent skills training only
Number of subjects: 715

Group type: COMPARATOR
Intervention: Parent and child skills training plus family skills training
Number of subjects: 715

Group type: COMPARATOR
Intervention: Minimal treatment controls
Number of subjects: 715
Study: 12679447

Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Number of subjects: 53

Group type: COMPARATOR
Intervention: Calorie‐restricted low fat diet
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 53
Study: 10616235

Group type: EXPERIMENTAL
Intervention: Ministernotomy (group M)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Median sternotomy (group S)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (M and S)
Number of subjects: 26
Study: 9457982

Group type: EXPERIMENTAL
Intervention: Morphologic hysteroscopic criteria (presence of endometrial glands presenting a cystic pattern)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Histology (as a comparison group)
Number of subjects: 95
Study: 2033429

Group type: EXPERIMENTAL
Intervention: Delayed rGM‐CSF (N = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rGM‐CSF (N = 6)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (N = 4)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (N = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early rGM‐CSF (N = 5)
Number of subjects: 30
Study: 7192488

Group type: EXPERIMENTAL
Intervention: Water-miscible vitamin A, 100,000 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water-miscible vitamin A, 50,000 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water-miscible vitamin A, greater than 100,000 IU
Number of subjects: 0
Study: 30072782

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) with slow rewarming for >48 hours
Number of subjects: 97

Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (MTH) with slow rewarming for ≤48 hours
Number of subjects: 97
Study: 27744007

Group type: EXPERIMENTAL
Intervention: NO3−-rich beetroot juice (140 mL day−1; 8.4 mmol NO3− day−1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: NO3−-depleted beetroot juice (0.08 mmol NO3− day−1)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: NO3−-rich beetroot juice (NIT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 17
Study: 25702160

Group type: EXPERIMENTAL
Intervention: Alerting tones with prism adaptation (PA) in young adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alerting tones with prism adaptation (PA) in older adults
Number of subjects: 0
Study: 23639243

Group type: EXPERIMENTAL
Intervention: TDF/FTC+ZDV
Number of subjects: 197

Group type: COMPARATOR
Intervention: TDF/FTC+EFV
Number of subjects: 197
Study: 20884893

Group type: EXPERIMENTAL
Intervention: HPV-and-treat (cryotherapy for positive HPV DNA test)
Number of subjects: 6637

Group type: EXPERIMENTAL
Intervention: Visual inspection-and-treat (cryotherapy for positive visual inspection)
Number of subjects: 6637

Group type: COMPARATOR
Intervention: Control (delayed evaluation or treatment for 6 months)
Number of subjects: 6637

Group type: EXPERIMENTAL
Intervention: HPV-and-treat
Number of subjects: 6637

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6637

Group type: EXPERIMENTAL
Intervention: Visual inspection-and-treat
Number of subjects: 6637
Study: 18186976

Group type: EXPERIMENTAL
Intervention: Artesunate-sulfamethoxypyrazine-pyrimethamine (AS-SMP) administered with a 12-h or 24-h interval between tablets.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AT-LU) given over 3 days.
Number of subjects: 14
Study: 16338010

Group type: EXPERIMENTAL
Intervention: OxLDL levels >76 U/L
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: OxLDL levels >76 U/L in TnT negative group
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 433

Group type: COMPARATOR
Intervention: OxLDL levels ≤76 U/L
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: OxLDL levels
Number of subjects: 433
Study: 14564381

Group type: EXPERIMENTAL
Intervention: Day hospital care
Number of subjects: 165

Group type: COMPARATOR
Intervention: Home treatment
Number of subjects: 165
Study: 10851665

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 30
Study: 8616946

Group type: EXPERIMENTAL
Intervention: Orgaran (750 anti-Factor Xa units subcutaneously every 12 hours for 14 days)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Aspirin (100 mg orally twice daily for 14 days)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Orgaran
Number of subjects: 251

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 251
Study: 1917227

Group type: EXPERIMENTAL
Intervention: Nandrolone-decanoate (100 mg weekly i.m. injection)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 7050440

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program consisting of stepped-care treatment for hypertension, counseling for cigarette smoking, and dietary advice for lowering blood cholesterol levels
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program
Number of subjects: 12866
Study: 3873785

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bypass surgery (subgroup analysis)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bypass surgery (beta blockers)
Number of subjects: 100
Study: 31363948

Group type: EXPERIMENTAL
Intervention: Proactive outreach intervention
Number of subjects: 939

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 939
Study: 29471132

Group type: EXPERIMENTAL
Intervention: High-intensity interval body weight training (HIBWT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Combined training (COMT)
Number of subjects: 16
Study: 27516093

Group type: EXPERIMENTAL
Intervention: Utidelone (25 to 35 mg/m2/day intravenously infused once daily for 5 days) in combination with capecitabine (2000 mg/m2 divided in two equal daily oral doses for 14 days)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Utidelone (40 mg/m2/day intravenously infused once daily for 5 days) as monotherapy
Number of subjects: 96
Study: 25056208

Group type: EXPERIMENTAL
Intervention: Public health outreach with culturally tailored educational materials (Group 1)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Individualized comprehensive cervical cancer CHW-led education session followed by patient navigation (Group 2)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Navigation to a Pap smear test or performing HPV self-sampling (Group 3)
Number of subjects: 600
Study: 22810619

Group type: EXPERIMENTAL
Intervention: CSE analgesia
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 1140

Group type: COMPARATOR
Intervention: PCIA with remifentanil
Number of subjects: 1140
Study: 20361306

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 20
Study: 18460588

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 125
Study: 16001377

Group type: EXPERIMENTAL
Intervention: 1CU Human Optics intraocular lens
Number of subjects: 20

Group type: COMPARATOR
Intervention: AcrySof intraocular lens
Number of subjects: 20
Study: 12461831

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 58

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 58
Study: 10624752

Group type: EXPERIMENTAL
Intervention: Tongue electrical stimulation (TES)
Number of subjects: 7
Study: 7733193

Group type: EXPERIMENTAL
Intervention: Adenoviral conjunctivitis
Number of subjects: 100
Study: 2109470

Group type: EXPERIMENTAL
Intervention: Flumazenil (36 micrograms.kg‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6270998

Group type: EXPERIMENTAL
Intervention: High fiber diet (59 g neutral detergent fiber)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet (21 g neutral detergent fiber)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low fiber diet (21 g neutral detergent fiber)
Number of subjects: 8
Study: 30394995

Group type: EXPERIMENTAL
Intervention: Cigarette and marijuana co-use
Number of subjects: 500
Study: 29432640

Group type: EXPERIMENTAL
Intervention: Diamond burs
Number of subjects: 12

Group type: COMPARATOR
Intervention: Curettes
Number of subjects: 12
Study: 25683164

Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 242

Group type: COMPARATOR
Intervention: Community practice control
Number of subjects: 242
Study: 25467093

Group type: EXPERIMENTAL
Intervention: Atenolol (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 80
Study: 22184645

Group type: EXPERIMENTAL
Intervention: Modified version of the Mother‐Infant Transaction Program
Number of subjects: 146

Group type: COMPARATOR
Intervention: Preterm control group
Number of subjects: 146

Group type: COMPARATOR
Intervention: Term reference group
Number of subjects: 146
Study: 20209375

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18160763

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB) - 50 mg of losartan potassium administered once daily for one year
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-ARB group (control)
Number of subjects: 19
Study: 15886228

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (6 mg)
Number of subjects: 27
Study: 10785238

Group type: EXPERIMENTAL
Intervention: 100 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 150 IU/d recombinant FSH starting on cycle day 5 with 0.25 mg/d GnRH antagonist from cycle day 8
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 150 IU/d recombinant FSH starting in the midfollicular phase
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: No luteal support provided
Number of subjects: 15
Study: 9301500

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Budesonide 4.5 mg twice daily
Number of subjects: 178

Group type: COMPARATOR
Intervention: Prednisolone 40 mg once daily
Number of subjects: 178
Study: 8280824

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg q.d.s., 7 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon (sodium alginate compound)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control period (no cimetidine)
Number of subjects: 12
Study: 3552444

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 32
Study: 31680010

Group type: EXPERIMENTAL
Intervention: BioFoam® Surgical Matrix
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (without use of BioFoam®)
Number of subjects: 101
Study: 30246557

Group type: EXPERIMENTAL
Intervention: HiBalance training program (10-week, three times per week, group-based, led by two physical therapists)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HiBalance training program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 100
Study: 28368158

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 48
Study: 25765696

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study: 23449130

Group type: EXPERIMENTAL
Intervention: Topical application of a mixture of Trifolium pratense flower extract and a biomimetic peptide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21593619

Group type: EXPERIMENTAL
Intervention: Twice-weekly peginterferon-α-2a 180 μg/week (for 4 weeks, followed by weekly dosing) and weight-based ribavirin (1-1.2 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly peginterferon-α-2a 180 μg/week and weight-based ribavirin (1-1.2 g/day)
Number of subjects: 0
Study: 19619692

Group type: EXPERIMENTAL
Intervention: Intravenous unfractionated heparin (UFH) bolus 70 IU/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin (1 mg/kg every 12 hours for 2.5 days)
Number of subjects: 72
Study: 16960935

Group type: EXPERIMENTAL
Intervention: Org 39141 (625 microg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14758100

Group type: EXPERIMENTAL
Intervention: Group 1: 70% of heart rate reserve using precise, continuous electronic heart rate‐controlled resistance on a cycle ergometer
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Group 2: Self-regulated exercise intensity at 'somewhat hard' (13 on the Borg scale) with no feedback
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Group 3: Exercise intensity determined using objective (heart rate reserve and work rate targeted to 60% to 80% of maximal exercise) and subjective (Borg scale 12 to 14) indices
Number of subjects: 78
Study: 11044536

Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) intravaginal gel (2 mg)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Prostaglandin E(2) intracervical gel (0.5 mg)
Number of subjects: 470
Study: 9340633

Group type: EXPERIMENTAL
Intervention: Autoset-CPAP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 12
Study: 8141719

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 800

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 800
Study: 3525584

Group type: EXPERIMENTAL
Intervention: Social skills training (SST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention placebo control (APC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No-treatment control (NTC)
Number of subjects: 50
Study: 29124498

Group type: EXPERIMENTAL
Intervention: RT1 (Resistance Training 1, n=26)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: RT2 (Resistance Training 2, n=27)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: RT3 (Resistance Training 3, n=28)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 106
Study: 27914492

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (90 mg twice daily) plus low-dose aspirin (81-100 mg daily) for 3 months, then ticagrelor plus placebo for 12 months
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Ticagrelor plus low-dose aspirin (81-100 mg daily) for 3 months, then continuation of ticagrelor plus aspirin
Number of subjects: 9000
Study: 25618415

Group type: EXPERIMENTAL
Intervention: GEMOXEL (GEM 1,000 mg/m², L-OHP 100 mg/m², CAP 1,500 mg/m²/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: GEM (GEM 1,000 mg/m²)
Number of subjects: 67
Study: 24524600

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation clinic follow‐up group (n = 70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional treatment group (n = 70)
Number of subjects: 140
Study: 21943132

Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy involving removal of subgingival and supragingival calculus and plaque biofilm by scaling and root‐planing.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (delayed intervention for 12 months).
Number of subjects: 0
Study: 18301974

Group type: EXPERIMENTAL
Intervention: Diet plus resistance training (DR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Diet only (D)
Number of subjects: 42
Study: 16530290

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment in CHB patients
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment in CHC patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 105

Group type: COMPARATOR
Intervention: Diseased controls (autoimmune liver diseases)
Number of subjects: 105
Study: 14580749

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Maltodextrins
Number of subjects: 87
Study: 10613766

Group type: EXPERIMENTAL
Intervention: Purple grape juice (5-7.5 mL/(kg. d) for 7-10 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Orange juice (5-7.5 mL/(kg. d) for 7-10 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Grapefruit juice (5-7.5 mL/(kg. d) for 7-10 days)
Number of subjects: 10
Study: 7981069

Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone
Number of subjects: 278

Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 278
Study: 2923769

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.25% bupivacaine through an extradural catheter
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.25% bupivacaine through a paravertebral catheter
Number of subjects: 20
Study: 30855076

Group type: EXPERIMENTAL
Intervention: GP endorsement via letter
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: GP endorsement via SMS
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Trust in GP
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Alternative endorsers suggested
Number of subjects: 110
Study: 29079990

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (2 × 10^9 CFU/g each of Lactobacillus acidophilus strain T16, Lactobacillus casei strain T2, and Bifidobacterium bifidum strain T1 plus 800 mg inulin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29103871

Group type: EXPERIMENTAL
Intervention: Olaparib (100 mg twice daily) plus paclitaxel (80 mg/m2 intravenously)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel (80 mg/m2 intravenously)
Number of subjects: 525
Study: 26412226

Group type: EXPERIMENTAL
Intervention: Learning and coping education strategies (LC)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Standard education (standard)
Number of subjects: 825
Study: 23627538

Group type: EXPERIMENTAL
Intervention: Harris coloured filters
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: DRT coloured filters
Number of subjects: 73
Study: 21797811

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 19028042

Group type: EXPERIMENTAL
Intervention: Cryo stripping
Number of subjects: 494

Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 494
Study: 17541058

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cortisone (25 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cortisone (25 mg) + Propranolol (40 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 42